Antidiabetic Medication Regimen Prior to Discharge
This patient should be transitioned to a subcutaneous multidose insulin regimen consisting of basal insulin plus pre-meal rapid-acting insulin (basal-bolus regimen) prior to discharge. 1
Transition from IV to Subcutaneous Insulin
The critical step is proper timing of the transition to prevent rebound hyperglycemia and recurrent DKA:
- Administer basal insulin (long-acting analog) 2-4 hours before discontinuing the IV insulin infusion to ensure adequate subcutaneous insulin action as the IV infusion is stopped 1
- Continue the IV insulin infusion after giving the subcutaneous basal insulin dose to bridge the gap and prevent metabolic decompensation 1
- Some evidence suggests administering low-dose basal insulin alongside the IV infusion may prevent rebound hyperglycemia without increasing hypoglycemia risk 1
Recommended Discharge Insulin Regimen
Basal-bolus insulin therapy is the standard of care for this patient:
- Basal insulin: Long-acting insulin analog (e.g., insulin glargine or detemir) once or twice daily, typically starting at 75-80% of calculated total daily dose or 0.2-0.4 units/kg/day 1, 2
- Bolus insulin: Rapid-acting insulin analog (e.g., insulin lispro, aspart, or glulisine) before each meal 1
- The average total daily insulin requirement typically ranges from 0.5-1 unit/kg/day for maintenance therapy 2
Critical Considerations for This Patient
Post-STEMI with DKA presents unique challenges:
- This patient has demonstrated insulin deficiency severe enough to cause DKA, indicating absolute need for insulin therapy 1
- The DIGAMI study demonstrated that intensive insulin treatment (IV insulin-glucose infusion followed by multidose subcutaneous insulin) in diabetic patients post-MI improved long-term survival with an absolute mortality reduction of 11% 3
- Insulin-requiring diabetes is independently associated with significantly higher mortality post-STEMI (hazard ratio 1.9) compared to non-diabetic patients 4, 5
Medications to AVOID at Discharge
SGLT2 inhibitors are absolutely contraindicated in this patient:
- SGLT2 inhibitors should have been discontinued 3-4 days before any major procedure and should NOT be restarted in the immediate post-DKA/post-PCI period 1
- Recent case reports demonstrate that SGLT2 inhibitors can cause euglycemic DKA even 5 days after discontinuation, particularly in post-cardiac surgery patients 6, 7
- One case documented SGLT2 inhibitor-associated EDKA precipitating acute coronary syndrome and cardiac arrest post-CABG 6
Metformin should be used with extreme caution or avoided initially:
- Given recent DKA and potential for renal dysfunction post-contrast exposure from PCI, metformin carries risk of lactic acidosis 1
- If considered later, ensure stable renal function (creatinine clearance >30 mL/min) before initiation
Discharge Planning Requirements
Structured discharge education is mandatory:
- Provide comprehensive education on DKA recognition, prevention, and management to prevent recurrence and readmission 1
- Schedule follow-up within 1-2 weeks (not 1 month) given the complexity of recent DKA and medication changes 1
- Ensure diabetes self-management education prior to discharge and medication reconciliation with attention to access 1
- Arrange frequent contact for therapy adjustments to avoid both hyperglycemia and hypoglycemia 1